Evidence map›Paper›PMID 35397534›Full record

ArticleMolecular medicine (Cambridge, Mass.)2022

The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo.

Lucía Beltrán-Camacho, Sara Eslava-Alcón, Marta Rojas-Torres, Daniel Sánchez-Morillo, Mª Pilar Martinez-Nicolás, Victoria Martín-Bermejo, Inés García de la Torre, Esther Berrocoso, Juan Antonio Moreno, Rafael Moreno-Luna and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Circulating angiogenic progenitor cell apoptosis in Post-COVID-19 syndrome.International journal of cardiology. Heart & vasculature · 2026
    Article
  3. Review
  4. Review
  5. Observational
  6. The Impact of Serum/Plasma Proteomics on SARS-CoV-2 Diagnosis and Prognosis.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Symptomatology and microbiology of the gastrointestinal tract in post-COVID conditions.JGH open : an open access journal of gastroenterology and hepatology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Lucía Beltrán-CamachoBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002, Cadiz, Spain.
Sara Eslava-AlcónBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002, Cadiz, Spain.
Marta Rojas-TorresBiomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002, Cadiz, Spain.
Daniel Sánchez-MorilloBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11002, Cadiz, Spain.
Mª Pilar Martinez-NicolásOccupational Health Service, National Paraplegic Hospital, SESCAM, 45071, Toledo, Spain.
Victoria Martín-BermejoOccupational Health Service, National Paraplegic Hospital, SESCAM, 45071, Toledo, Spain.
Inés García de la TorrePhysiotherapy Service, National Paraplegic Hospital, SESCAM, 45071, Toledo, Spain.
Esther BerrocosoBiomedical Research and Innovation Institute of Cadiz (INiBICA), 11002, Cadiz, Spain.
Juan Antonio MorenoMaimonides Biomedical Research Institute of Cordoba (IMIBIC), UGC Nephrology, Reina Sofía University Hospital, 14004, Cordoba, Spain.
Rafael Moreno-Luna *Laboratory of Neuroinflammation, National Paraplegic Hospital, SESCAM, 45071, Toledo, Spain.
Mª Carmen Durán-Ruiz *Biomedicine, Biotechnology and Public Health Department, University of Cadiz, 11002, Cadiz, Spain. maricarmen.duran@gm.uca.es.ORCID 0000-0003-3954-3734
Universidad de Cádiz · ESServicio de Salud de Castilla La Mancha · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused 6 million deaths worldwide. While asymptomatic individuals are responsible of many potential transmissions, the difficulty to identify and isolate them at the high peak of infection constitutes still a real challenge. Moreover, SARS-CoV-2 provokes severe vascular damage and thromboembolic events in critical COVID-19 patients, deriving in many related deaths and long-hauler symptoms. Understanding how these processes are triggered as well as the potential long-term sequelae, even in asymptomatic individuals, becomes essential.

methodsWe have evaluated, by application of a proteomics-based quantitative approach, the effect of serum from COVID-19 asymptomatic individuals over circulating angiogenic cells (CACs). Healthy CACs were incubated ex-vivo with the serum of either COVID-19 negative (PCR -/IgG -, n:8) or COVID-19 positive asymptomatic donors, at different infective stages: PCR +/IgG - (n:8) and PCR -/IgG + (n:8). Also, a label free quantitative approach was applied to identify and quantify protein differences between these serums. Finally, machine learning algorithms were applied to validate the differential protein patterns in CACs.

resultsOur results confirmed that SARS-CoV-2 promotes changes at the protein level in the serum of infected asymptomatic individuals, mainly correlated with altered coagulation and inflammatory processes (Fibrinogen, Von Willebrand Factor, Thrombospondin-1). At the cellular level, proteins like ICAM-1, TLR2 or Ezrin/Radixin were only up-regulated in CACs treated with the serum of asymptomatic patients at the highest peak of infection (PCR + /IgG -), but not with the serum of PCR -/IgG + individuals. Several proteins stood out as significantly discriminating markers in CACs in response to PCR or IgG + serums. Many of these proteins particiArticle title: Kindly check and confirm the edit made in the article title.pate in the initial endothelial response against the virus.

conclusionsThe ex vivo incubation of CACs with the serum of asymptomatic COVID-19 donors at different stages of infection promoted protein changes representative of the endothelial dysfunction and inflammatory response after viral infection, together with activation of the coagulation process. The current approach constitutes an optimal model to study the response of vascular cells to SARS-CoV-2 infection, and an alternative platform to test potential inhibitors targeting either the virus entry pathway or the immune responses following SARS-CoV-2 infection.

Indexed as

COVID-19HumansImmunoglobulin GNucleic Acid Amplification TechniquesSARS-CoV-2Immunoglobulin GAsymptomaticCirculating angiogenic cellsCOVID-19Endothelial dysfunctionEndothelial progenitor cellsProteomicsSARS-CoV-2

Identifiers

PMID35397534
PMCPMC8994070
OpenAlexW4223608236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.